British Journal of Renal Medicine - 2019


School's out – the challenge of chronic kidney disease for young people
John Bradley
pp 31-31

Chronic kidney disease impacts on many aspects of a child’s life. Even children with mild-to-moderate chronic kidney disease tend to experience a reduced health-related quality of life, with functioning at school being a particular concern. Physical illness, interference with school attendance because of medical care, and impairment of neurocognitive function may all contribute to poorer academic performance.

Can the Essential Dialysis Nutrition Adult screening tool (EDNA) identify haemodialysis patients at risk of malnutrition?
Kim Bowra, Claire Gardiner, David Keane and Aly Woodall
pp 32-36

Over three million people in the UK are estimated to be at risk of malnutrition at any one time, contributing a significant 15% to national health and social care expenditure.

National Kidney Federation
Pauline Pinkos
pp 36-36

The opt-out system of organ donation in England has been passed into law and is expected to save up to 700 lives a year. The legislation will take effect in Spring 2020 and will mean adults will be assumed to be donors unless they chose to opt-out.

Analgesic use among dialysis patients within one UK health board
Andrew McCallum, Lauren Dickson, Sue Robertson, Alison Almond, Nadeeka Rathnamalala, Michael J Kelly and Thalakunte Muniraju
pp 37-39

Pain is commonly experienced by long-term dialysis patients, with studies reporting a prevalence of between 50% and 82%. Although published guidelines for the management of such pain are available, inadequate treatment remains common. Concerns about treatment adequacy and the adverse effects of analgesics may partly explain the variability in opioid prescribing rates between centres in the USA, with the incidence of opioid prescription for dialysis patients ranging between 5% and 64%.

British Renal Society
Maarten Taal
pp 39-39

For most people in kidney care, multiprofessional working is a normal part of our daily experience. Nurses, psychologists, dieticians, managers, pharmacists, therapists, technicians and doctors all work together in integrated teams to provide the best possible patient-centred care, and we enjoy doing it. For many, multiprofessional working is one of the attractions of a career in kidney care.

Ocular bleeding: a case report and brief review of eye disease in chronic kidney disease
James Stanway Neil Shah and Aine Burns
pp 40-42

Eye disease frequently complicates chronic kidney disease (CKD). Here we report a severe presentation of a common complication of diabetic retinopathy in a patient on haemodialysis and review the ophthalmic complications of CKD.

Kidney Research UK

pp 42-42

The Surveying People Experiencing young Adult Kidney failure (SPEAK) study highlights the challenges faced by young people on dialysis or with a kidney transplant. The study was led by Dr Alex Hamilton, at the University of Bristol and Southmead Hospital. Dr Hamilton recently delivered the Raine lecture at UK Kidney Week in Brighton, based on this work.

Should dietary phosphate be restricted at stage 3 chronic kidney disease?
Maria P Barrett and Indranil Dasgupta
pp 45-47

When healthcare professionals think of the ‘renal diet’, their thoughts might first go to the importance of a dietary potassium restriction. Dietary salt restriction is likely a close second. However, emerging evidence is highlighting the vital importance of dietary phosphate restriction, ideally as early as stage 3b chronic kidney disease.

It’s all about the workforce
Donal J O’Donoghue
pp 48-49

When the NHS was first established in 1948, it was supported by a workforce of around 144,000 people. Now, 70 years later, the NHS is the largest employer in the UK, with around 1.1 million full-time equivalent (FTE) staff in hospital and community services in England alone. Our people are the health system’s greatest asset. Without its many different members of staff – think of all the types of staff that make a renal unit work – there would be no health service.

The Renal Association
Matthew Graham-Brown and Elizabeth Wallin
pp 50-50

A new era for the Renal Association SpR Club

Kidney Care UK
Fiona Loud
pp 50-50

The law on organ donation in England is changing - pass it on. 

Renal cell carcinoma: novel medical therapies and management of renal toxicities
Faouzi Djebbari, Laura Spiers, David Mole, Andrew Protheroe and Mark Tuthill
pp 51-55

Kidney cancer is the seventh most common cancer in the UK, with approximately 12,500 new cases diagnosed in 2014, accounting for 3% of all new cancer cases, and its incidence has increased by 78% since the 1990s. Renal cell carcinoma (RCC) accounts for 90% of all kidney cancers and usually originates within the lining of the tubules of the kidney. Over the last two decades, the treatment of advanced and metastatic RCC has been revolutionised by an increased understanding of the biology of the disease and the use of tyrosine kinase inhibitors as well as anti-angiogenic drugs. This has translated into significant improvement in overall survival of patients with kidney cancer. In the last two years, treatment options have been further improved with the introduction of immune checkpoint inhibitors.

The British Journal of Renal Medicine was previously supported by Baxter Healthcare from 2011 to 2013, by Sandoz in 2011, by Shire Pharmaceuticals from 2006 to 2011, by Ortho Biotech and Shire Pharmaceuticals in 2005, by Ortho Biotech from 2000 to 2005 and by Janssen Cilag from 1996 to 2000.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title British Journal of Renal Medicine is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1365-5604 (Print)  ISSN 2045-7839 (Online)